Tagged Articles

bleeding risks 7 articles

NHL’s Stamkos benched due to injury, blood thinners

Professional ice hockey center and team captain for the Tampa Bay Lightning Steven Stamkos likely won’t be playing anytime soon after suffering a blood clot last March because his treatment puts him at risk for serious bleeding risks in the event he is injured. Stamoks is lucky, though. He suffered pain and swelling in his right arm after a game against the Canadiens – something a lot of people would have dismissed – and immediately associated it with symptoms his teammate Andrei Vasilevskiy had experienced. Vasilevskiy had been diagnosed with thoracic outlet syndrome. The condition, which occurs when the upper ... Read More

Dangerous side effects linked to 3 Johnson & Johnson prescription drugs

Janssen Pharmaceuticals was founded in 1953 and purchased by Johnson & Johnson in 1961. The company is now part of Johnson & Johnson Pharmaceutical Research and Development, which conducts research and development activities for treatments for a variety of conditions including mental illness, neurological disorders, gastrointestinal disorders, fungal infections, allergies and cancer. While its medications aim to improve health, some carry serious side effects. Janssen and its parent company has been charged time and time again of withholding side effects data in an effort to increase profits. Here are some Johnson & Johnson/Janssen medications that have been linked to serious ... Read More

Black box warning for bleeding risks added to antiplatelet Brilinta

The safety label for the oral antiplatelet drug Brilinta (ticagrelor) has been updated to include a new boxed warning for serious bleeding risks and a lessening of effectiveness when taken with maintenance doses of aspirin above 100 mg. Brilinta, made by AstraZeneca, is used with low-dose aspirin to help prevent heart attacks and stokes in people with heart problems such as unstable angina or previous heart attack, as well as in patients with acute coronary syndrome (ACS). It is also used to reduce the risk of stent thrombosis in patients who have been stented for the treatment of ACS. Like ... Read More

Boehringer Ingelheim to pay $650 million to resolve Pradaxa lawsuits

Boehringer Ingelheim announced it will pay $650 million to resolve about 4,000 state and federal lawsuits alleging the company’s blood thinner Pradaxa caused patients to suffer serious bleeding events. Boehringer Ingelheim denied any wrongdoing and said the settlement is being offered to avoid lengthy litigation. The drug company said it expects most, if not all, the plaintiffs to accept the terms of the settlement, and it will vigorously defend itself against those who do not. Pradaxa (dabigatran) was the first drug to be approved from a new class of blood thinners. The drug has been plagued with reports of excessive ... Read More

Officials offer theories why Pradaxa associated with so many bleeding events


Theories abound as to why bleeding risks with the blood thinner Pradaxa (dabigatran) appear greater than the long-used Coumadin (warfarin). In a perspective published online in the New England Journal of Medicine, Food and Drug Administration (FDA) officials speculate the concern may be due to the heightened sensitivity and vigilance that generally accompany new drugs. Pradaxa is a new class of blood thinner that was approved by the FDA in 2010 to prevent strokes in patients with a common but life-threatening type of abnormal heart rhythm known as atrial fibrillation. It became one of the first alternatives to warfarin, and ... Read More

Atrial fibrillation patients should be aware of risks associated with Pradaxa vs. Warfarin


Anticoagulants are often given to patients with a type of heart rhythm abnormality known as atrial fibrillation to prevent strokes. The reasoning is that in people with atrial fibrillation, the upper chambers of the heart pump abnormally causing blood to pool in the atria. When that happens, blood clots are more likely to form. If a blood clot gets pumped out of the heart and lodges in a blood vessel in the brain, it can cause a stroke. Anticoagulants thin the blood and help prevent clots from forming, which, in turn, help prevent strokes from occurring in patients with atrial ... Read More

FDA’s analysis of bleeding risks with Pradaxa could be ‘problematic’


The Food and Drug Administration’s approach to analyzing bleeding risks with the new blood thinner Pradaxa “may be worth reviewing” because the process may be problematic, Forbes magazine claims in a recent story. Pradaxa was approved by the FDA in late 2010 for the prevention of strokes in patients with atrial fibrillation. It was one of the first blood thinners cleared for this use since warfarin was approved more than 50 years ago. In the first 14 months since its approval, Pradaxa has been linked to more than 500 deaths and hundreds more side effects than any other drug, according ... Read More